IceCure Medical (NASDAQ:ICCM - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02, RTT News reports. The business had revenue of $0.73 million for the quarter, compared to analysts' expectations of $0.75 million. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. During the same period in the prior year, the company posted ($0.08) EPS.
IceCure Medical Price Performance
ICCM traded up $0.02 during trading on Friday, reaching $1.05. 166,926 shares of the stock were exchanged, compared to its average volume of 474,073. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.27. The company has a market capitalization of $58.28 million, a price-to-earnings ratio of -3.62 and a beta of 0.41. IceCure Medical has a 1 year low of $0.48 and a 1 year high of $1.66. The business's 50 day moving average price is $1.11 and its two-hundred day moving average price is $1.13.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a "buy" rating and set a $2.50 target price on shares of IceCure Medical in a research report on Thursday.
Check Out Our Latest Research Report on IceCure Medical
IceCure Medical Company Profile
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
See Also
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
